Preclinical Alzheimer's disease

被引：1
|
作者：
Gil-Gregorio, P. [1 ]
Yubero-Pancorbo, R. [1 ]
机构：
[1] Hosp Clin San Carlos, Dept Geriatr, Memory Unit, Madrid, Spain
来源：
REVIEWS IN CLINICAL GERONTOLOGY | 2014年 / 24卷 / 02期
关键词：
Alzheimer's disease; preclinical stages; amyloidosis; neurodegeneration; cognition;
D O I：
10.1017/S095925981400001X
中图分类号：
R592 [老年病学]; C [社会科学总论];
学科分类号：
03 ; 0303 ; 100203 ;
摘要：
Recently, diagnostic criteria for preclinical Alzheimer's disease have been proposed. These describe and define three stages of disease. Stage I is focused on asymptomatic cerebral amyloidosis. Stage II includes evidence of synaptic dysfunction and/or early degeneration. Finally, stage III of the disease is characterized by the beginning of cognitive decline.
引用
收藏
页码：117 / 121
页数：5
相关论文
共 50 条
  • [41] Medial temporal lobe gray matter microstructure in preclinical Alzheimer's disease
    Brown, Christopher
    Das, Sandhitsu
    Xie, Long
    Nasrallah, Ilya
    Detre, John
    Chen-Plotkin, Alice
    Shaw, Leslie
    McMillan, Corey
    Yushkevich, Paul
    Wolk, David
    ALZHEIMERS & DEMENTIA, 2024, 20 (06) : 4147 - 4158
  • [42] Progress in blood biomarkers of subjective cognitive decline in preclinical Alzheimer's disease
    Yu, Xianfeng
    Shao, Kai
    Wan, Ke
    Li, Taoran
    Li, Yuxia
    Zhu, Xiaoqun
    Han, Ying
    CHINESE MEDICAL JOURNAL, 2023, 136 (05) : 505 - 521
  • [43] Neurocognitive effects of proanthocyanidin in Alzheimer's disease: a systematic review of preclinical evidence
    Reshma, A.
    Subramanian, A.
    Kumarasamy, V.
    Tamilanban, T.
    Sekar, M.
    Gan, S. H.
    Subramaniyan, V.
    Wong, L. S.
    Rani, N. N. I. M.
    Wu, Y. S.
    BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH, 2024, 57
  • [44] Detecting cognitive changes in preclinical Alzheimer's disease: A review of its feasibility
    Mortamais, Marion
    Ash, Jessica A.
    Harrison, John
    Kaye, Jeffrey
    Kramer, Joel
    Randolph, Christopher
    Pose, Carine
    Albala, Bruce
    Ropacki, Michael
    Ritchie, Craig W.
    Ritchie, Karen
    ALZHEIMERS & DEMENTIA, 2017, 13 (04) : 468 - 492
  • [45] Development of memantine as a drug for Alzheimer's disease: A review of preclinical and clinical studies
    Althobaiti, Yusuf S.
    TROPICAL JOURNAL OF PHARMACEUTICAL RESEARCH, 2020, 19 (07) : 1535 - 1540
  • [46] Recommended cognitive outcomes in preclinical Alzheimer's disease: Consensus statement from the European Prevention of Alzheimer's Dementia project
    Ritchie, Karen
    Ropacki, Michael
    Albala, Bruce
    Harrison, John
    Kaye, Jeffrey
    Kramer, Joel
    Randolph, Christopher
    Ritchie, Craig W.
    ALZHEIMERS & DEMENTIA, 2017, 13 (02) : 186 - 195
  • [47] Are Parkinson's Disease Patients the Ideal Preclinical Population for Alzheimer's Disease Therapeutics?
    Tropea, Thomas F.
    Chen-Plotkin, Alice
    JOURNAL OF PERSONALIZED MEDICINE, 2021, 11 (09):
  • [48] Subjective cognitive decline: preclinical manifestation of Alzheimer’s disease
    Yan Lin
    Pei-Yan Shan
    Wen-Jing Jiang
    Can Sheng
    Lin Ma
    Neurological Sciences, 2019, 40 : 41 - 49
  • [49] Slowed Driving Reaction Time in Preclinical Alzheimer's Disease
    Ahmadnezhad, Pedram
    Burns, Jeffrey M.
    Akinwuntan, Abiodun E.
    Ranchet, Maud
    Kondyli, Alexandra
    Babulal, Ganesh M.
    Mahnken, Jonathan D.
    Devos, Hannes
    JOURNAL OF APPLIED GERONTOLOGY, 2025,
  • [50] Longitudinal brain structural changes in preclinical Alzheimer's disease
    Pegueroles, Jordi
    Vilaplana, Eduard
    Montal, Victor
    Sampedro, Frederic
    Alcolea, Daniel
    Carmona-Iragui, Maria
    Clarimon, Jordi
    Blesa, Rafael
    Lleo, Alberto
    Fortea, Juan
    ALZHEIMERS & DEMENTIA, 2017, 13 (05) : 499 - 509
12345